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Abstract 
Backgroud: BST-2 is an interferon-induced host restriction factor that inhibits the release of diverse mammalian 
enveloped viruses from infected cells by physically trapping the newly formed virions onto the host cell surface. 
Human Immunodeficiency Virus-1 (HIV-1) encodes an accessory protein Vpu that antagonizes BST-2 by down-regulat-
ing BST-2 from the cell surface.
Results: Using a cell-based ELISA screening system, we have discovered a lead compound, 2-thio-6-azauridine, that 
restores cell surface BST-2 level in the presence of Vpu. This compound has no effect on the expression of BST-2 and 
Vpu, but inhibits Vpu-mediated BST-2 down-regulation and exerts no effect on Vpu-induced down-regulation of CD4 
or KSHV K5 protein induced BST-2 down-regulation. 2-thio-6-azauridine suppresses HIV-1 production in a BST-2-de-
pendent manner. Further results indicate that 2-thio-6-azauridine does not interrupt the interaction of BST-2 with Vpu 
and β-TrCP2, but decreases BST-2 ubiquitination.
Conclusion: Our study demonstrates the feasibility of using small molecules to target Vpu function and sensitize 
wild type HIV-1 to BST-2-mediated host restriction.
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Background
Human bone marrow stromal cell antigen 2 (BST-2, also 
called Tetherin, CD317 or HM1.24) was first shown to 
inhibit HIV-1 production by physically trapping the 
newly formed virions onto the host cell surface [1, 2]. Its 
antiviral spectrum was subsequently expanded to other 
enveloped viruses including retroviruses, arenaviruses, 
herpesviruses, and filoviruses [2–9]. BST-2 is a 28- to 
36-kDa type II integral membrane glycoprotein, located 
to lipid rafts at the plasma membrane and the trans Golgi 
network (TGN). It consists of four domains, a short 
N-terminal cytoplasmic tail, an N-terminal transmem-
brane region (TMR), an extracellular coiled-coil domain 
and a C-terminal glycosyl-phosphatidylinositol (GPI) 
anchor [10–12]. The unique topology that is determined 
by the GPI anchor and the coiled-coil structure, rather 
than by the amino acid sequence, confers its virus-tether-
ing activity [1, 13].
Many viruses have evolved countermeasures to over-
come BST-2 restriction [4, 14–20]. In HIV-1, a 16-kDa 
accessory protein Vpu fulfills this role. Vpu is also an 
integral membrane protein, which belongs to type I inte-
gral membrane protein family. It performs two distinct 
functions in HIV-1 infection: causing CD4 degradation 
in the endoplasmic reticulum and promoting viral parti-
cle release by counteracting BST-2 [21–28]. The mecha-
nisms underlying Vpu’s antagonistic activity against 
BST-2 involve a direct interaction between their respec-
tive transmembrane (TM) domains, targeting BST-2 to 
beta Transducin-repeat Containing Protein2 (β-TrCP2) 
dependent lysosomal and/or proteasomal degradation 
pathway [14, 29–31], or simply trapping BST-2 within the 
TGN [32, 33]. Since studies have demonstrated decreases 
in levels of both the total cellular BST-2 as well as the cell 
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surface BST-2 by Vpu [29, 34–37], both the lysosomal 
and the proteasomal degradation pathways may have a 
role in Vpu antagonization of BST-2.
BST-2 is constitutively expressed in many human cell 
types including B cells, T cells, monocytes, macrophages, 
plasmacytoid dendritic cells (PDCs) as well as cell lines 
such as HeLa, H9 and Jurkat [1, 34, 38]. Since the nat-
ural HIV-1 target cells are among the above list, block-
ing Vpu-mediated BST-2 down-regulation represents an 
attractive strategy for developing new anti-HIV drugs. In 
the previous study, we have developed a high-throughput 
cell-based ELISA assay to monitor cell surface BST-2 
level. This assay has been successfully utilized to identify 
small molecules that antagonize HIV-1 Vpu function and 
thus inhibit HIV-1 production by rescuing the antiviral 
activity of BST-2 [39].
Results
2‑thio‑6‑azauridine inhibits Vpu‑mediated 
down‑regulation of cell surface BST‑2
We have previously developed a high-throughput cell-
based ELISA assay for screening small molecules that 
prevent HIV-1 Vpu from degrading BST-2 [39]. Briefly, 
we firstly established a stable Vpu-expressing HeLa cell 
line, HeLa-Vpu, which continuously expresses Vpu and 
down-regulates the BST-2 level on the cell surface. Next, 
we fixed the cells in 96-well microplates and monitored 
the cell surface BST-2 level using enzyme-linked Cell-
ELISA. After optimization and evaluation, the assay 
model was adapted to a cell-based high-throughput 
screening (HTS) assay to identify compounds that inhibit 
Vpu-mediated BST-2 degradation (Fig. 1a).
Using this assay, we performed a screening test against 
56,000 compounds in the chemical library and natural 
product collection at the Institute of Medicinal Biotech-
nology at a concentration of 10  μM. A positive hit was 
defined a priori as a compound that would increase cell 
ELISA optical density at OD450 by more than 3 stand-
ard deviations (SD) in the primary screen. Positive hits 
were then tested further to exclude a possible false-pos-
itive effect due to optical density of compound. Finally, 
the positive compounds were tested for cellular toxicity 
effects, dose–response assessments and anti-HIV activi-
ties. In the end, three compounds including 2-thio-6- 
azauridine (MW 261.26, Fig.  1b) were identified to be 
effective in restoring cell ELISA optical density at OD450, 
the value that reflects the cell surface level of BST-2. Pre-
vious reports and our data showed that 2-thio-6-azaur-
idine was a low toxicity compound with antitumor and 
antivirus activity [40, 41]; we therefore chose 2-thio-
6-azauridine for further mechanism investigation. Ini-
tial results revealed that 2-thio-6-azauridine is capable 
of restoring BST-2 level on the cell surface, which were 
determined using the cell ELISA and a FACS analysis 
(Fig. 1c, left and middle panels). Results of Western blots 
confirmed that 2-thio-6-azauridine can significantly 
restore BST-2 expression in the presence of HIV-1 Vpu, 
a property that is shared by the lysosomal inhibitor Con-
canamycin A (ConA) (Fig. 1c, right panel).
In order to determine whether this effect of 2-thio-
6-azauridine is specific to Vpu, we treated HeLa-Vpu 
and HeLa cells with increasing concentrations of 2-thio-
6-azauridine (0.05, 0.5, 5 µM) respectively for 24 h, and 
then measured the cell surface levels of BST-2 by cell-
ELISA. A dose-dependent increase of the BST-2 lev-
els was observed only in HeLa-Vpu cells, not in HeLa 
cells (Fig.  1d). The similar results were obtained using 
the FACS analysis (Additional file  1). These data sug-
gest that 2-thio-6-azauridine increases the cell surface 
BST-2 not simply by up-regulating the expression of 
BST-2. We also measured the bst-2 mRNA level in HeLa-
Vpu and HeLa cells using real-time RT-PCR. The results 
showed that the compound had nearly no effect on bst-2 
mRNA level in both cell lines, which further confirms 
that 2-thio-6-azauridine does not affect BST-2 expres-
sion (Fig. 1e). We next examined the possibility whether 
2-thio-6-azauridine affects Vpu expression. The results of 
Western blotting showed no effect of 2-thio-6-azauridine 
on Vpu level in the HeLa-Vpu cells (Fig. 1f ). Taken alto-
gether, our results indicate that 2-thio-6-azauridine does 
not affect the expression of BST-2 or Vpu, which suggests 
that 2-thio-6-azauridine restores the level of cell surface 
BST-2 by inhibiting Vpu-mediated BST-2 degradation.
2‑thio‑6‑azauridine inhibits HIV‑1 production in a BST‑2 
dependent manner
Since 2-thio-6-azauridine prevents Vpu from down-regu-
lating BST-2, we next tested whether 2-thio-6-azauridine 
inhibits the production of pseudotyped HIV-1 in the 
presence of BST-2. Plasmids pNL-Luc-E- and pHIT/G 
were co-transfected with either pBST-2 or the control 
vector into 293T cells that do not express endogenous 
BST-2. Cells were treated with 5  μM of 2-thio-6-azau-
ridine at 24  h post transfection. Viruses in the culture 
supernatant were harvested at 48 h post transfection. The 
amounts of viruses were determined by measuring p24 
in the supernatant (Additional file  2A). Equal amounts 
of viruses were used to infect SupT1 cells to determine 
virus infectivity. As shown in Fig. 2a, 2-thio-6-azauridine 
treatment reduced virus amount in the supernatant by 
approximately 60  % in the presence of BST-2, whereas 
no significant effect was seen in the absence of BST-2. 
A 60 % decrease was detected in virus infectivity in the 
presence of BST-2. These data suggest that 2-thio-6-azau-
ridine sensitizes the wild type HIV-1 to BST-2 restriction 
by preventing Vpu from countering BST-2.
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Fig. 1 2-thio-6-azauridine inhibits Vpu-mediated down-regulation of cell surface BST-2. a Illustration of the assay that was used to screen small mol-
ecules that antagonize HIV-1 Vpu function and inhibit BST-2 degradation. b Structure of 2-thio-6-azauridine. c HeLa and HeLa-Vpu cells were treated 
by 2-thio-6-azauridine for 24 h. Levels of cell surface BST-2 were detected using cell-ELISA (left panel), flow cytometry (middle pannel) or Western 
blotting (right panel) (d) HeLa-Vpu and HeLa cells were treated with increasing concentrations of 2-thio-6-azauridine (0.05, 0.5, 5 µM) for 24 h. Cell 
surface BST-2 was measured using cell-ELISA. (e) HeLa and HeLa-Vpu cells were treated with DMSO, 2-thio-6-azauridine (5 µM) and ConA (50 nM) 
for 24 h respectively. The amounts of bst-2 mRNA were measured by real-time RT-PCR. The bst-2 mRNA values are normalized to those in the control 
cells that were treated with DMSO. f HeLa-Vpu cells were treated with DMSO, 2-thio-6-azauridine (5 µM) and ConA (50 nM) for 24 h respectively. 
Western blots of cell lysates were probed with anti-Vpu (top panel) and anti-β-actin (bottom panel) antibodies, respectively. (*p < 0.05, t test)
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We next tested the effect of 2-thio-6-azauridine on 
the antiviral activity of endogenous BST-2. To this 
end, a BST-2 knockdown HeLa cell line, named HeLa-
shRNA-BST-2, was generated. Results of Western blot-
ting showed that this cell line expressed almost no BST-2 
(Fig.  2b, left panel). As a result, this cell line produced 
7 to eightfold more Vpu-deficient HIV-1 than the con-
trol HeLa cells (Fig. 2b, right panel). 2-thio-6-azauridine 
reduced the HIV-1 release and infectivity by approxi-
mately threefold in HeLa cells with an approximate 
IC50 value of 0.22  ±  0.013  μM. On the other hand, 
2-thio-6-azauridine only showed a marginal inhibition 
effect against HIV-1 in HeLa-shRNA-BST-2 cells (IC50: 
4.42  ±  0.004  μM, Fig.  2c, d, Additional file  2B). These 
results demonstrate that 2-thio-6-azauridine inhibits 
HIV-1 replication mainly through protecting BST-2 from 
Vpu-induced degradation.
To further validate the inhibitory effect of 2-thio-
6-azauridine upon the virus release in the presence of 
BST-2, we performed a standard HIV particle release 
assay by western blotting. This assay involves quantitat-
ing the ratio of virion-associated Gag p24 in the superna-
tant relative to cell-associated Gag p55 in the cell lysates. 
As shown in Fig.  3a, 2-thio-6-azauridine only showed a 
marginal inhibition effect (less than 20 %) on HIV-1 Gag 
expression, while virion-associated p24 was reduced by 
more than 60 %. This result is consistent with that of p24 
quantification using the ELISA (Fig. 2a).
It is also noteworthy that the reduction in viral infec-
tivity by 2-thio-6-azauridine is more significant than that 
of virus production, suggesting that in addition to restor-
ing BST2 levels at the cell surface and thereby impeding 
the release of HIV-1 particles, the compound may affect 
another step in the virus life cycle. Therefore, we fur-
ther examined the effect of 2-thio-6-azauridine on Gag 
processing and VSVg pseudotyping. Interestingly, with 
increasing amount of 2-thio-6-azauridine, we observed 
gradual increase in the ratio of immature viral protein 
(including Gag p55 and its immature derivatives) relative 
to mature viral protein p24 (Fig.  3b). This suggests that 
the compound impairs viral Gag processing. A previous 
work showed that BST-2 somehow interferes with the 
activation of viral protease [42]. Taken together, these 
data suggest that restored BST-2 levels by the compound 
inhibit viral release and consequently impede maturation 
of HIV-1 particles.
We next examined the inhibitory effect of 2-thio-
6-azauridine on the replication of wild type HIV-1 in 
human primary mononuclear cells. The equal amounts 
of cord blood mononuclear cells (CBMCs) were infected 
with fully infectious wild type HIV-1 strain NL4-3, fol-
lowed by measuring viral reverse transcriptase activity to 
determine the amounts of virus in culture supernatants. 
The compound showed potent activity against the repli-
cation of wild type HIV-1 in human primary cells (Fig. 4).
2‑thio‑6‑azauridine specifically inhibits Vpu‑induced 
degradation of BST‑2
We next asked whether 2-thio-6-azauridine specifically 
inhibits Vpu-induced degradation of BST-2. To answer 
this question, we first tested the effect of 2-thio-6-azau-
ridine on IFN-α-triggered degradation of IFN-α recep-
tor 1 (IFNAR1). IFNAR1 is a type I membrane protein. 
Interferon stimulation leads to IFNAR1 phosphorylation 
followed by β-TrCP2-dependent lysosomal degradation. 
This degradation model is similar to Vpu-induced BST-2 
degradation (Fig.  5a) [43]. HeLa cells were first trans-
fected with a plasmid expressing Flag-tagged IFNAR1. 
Then, cells were treated with actidione 40  h post trans-
fection to block IFNAR1 synthesis. IFN-α was added to 
cells to induce lysosomal degradation of IFNAR1. 2-thio-
6-azauridine was also added in the presence of IFN-α. As 
shown in Fig.  5b, IFN-α reduced IFNAR1 level and the 
lysosomal inhibitor ConA restored IFNAR1 expression. 
By contrast, 2-thio-6-azauridine had no effect on the 
IFN-induced IFNAR1 degradation. These data suggest 
that 2-thio-6-azauridine is specific in preventing Vpu-
induced BST-2 degradation and has no general effect on 
the lysosomal degradation pathway.
In order to further demonstrate this specificity of 
2-thio-6-azauridine toward Vpu/BST-2, we examined 
the effect of 2-thio-6-azauridine on Vpu-mediated deg-
radation of CD4. It is known that Vpu down-regulates 
CD4 in the endoplasmic reticulum through β-TrCP-
dependent degradation, and the treatment with protea-
some inhibitor MG132 blocks the degradation process. 
Plasmid expressing CD4 was first transfected to HeLa 
or HeLa-Vpu cells, followed by treating the cells with 
5  μM of 2-thio-6-azauridine at 24  h post transfection. 
The CD4-positive cells were scored by flow cytometry at 
48 h post transfection (Additional file 3A). As shown in 
Fig.  6a, CD4 levels in the presence of Vpu were almost 
unchanged with the treatment of 2-thio-6-azauridine, 
while the addition of MG132 significantly increased the 
CD4 content. By contrast, either 2-thio-6-azauridine or 
MG132 exhibited no significant effect upon CD4 in the 
absence of Vpu. The results suggest that 2-thio-6-azaur-
idine specifically inhibits Vpu-induced BST-2 degrada-
tion and has no inhibitory effect to other function of Vpu 
protein.
BST-2 has been shown to inhibit the release of a variety 
of enveloped viruses, such as HIV-2, Simian Immunode-
ficiency Viruses, Kaposi’s sarcoma- associated herpesvi-
rus (KSHV), etc. [3, 4, 18, 20, 44]. These viruses have also 
developed various mechanisms to counteract the activity 
of BST-2. For example, KSHV encodes  a RING-CH  E3 
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Fig. 2 2-thio-6-azauridine inhibits HIV-1 in a BST-2-dependent manner. a Single-round pseudotyped HIV-1 expressing plasmids pNL-Luc-E- and 
pHIT/G were co-transfected with pBST-2 which expresses HA tagged BST-2 or the control vector to 293T cells. 24 h post transfection, the cells were 
treated with 5 μM of 2-thio-6-azauridine. Viruses in the culture supernatants were harvested at 48 h post transfection. Viral p24 and virus infectivity 
were measured as described in “Methods”. b Establishment of HeLa-shRNA-BST-2 cells, a BST-2 knockdown HeLa cell line. Western blot detection of 
BST-2 expression in HeLa and HeLa-shRNA-BST-2 cells is shown in the left panel. Results of relative infectivity assay using a single-round HIV-1 infec-
tion in HeLa and HeLa-shRNA-BST-2 cells are shown in the right panel. c HeLa and HeLa-shRNA-BST-2 cells were co-transfected with plasmids pNL-
Luc-E- and pHIT/G to produce single-round HIV-1 particles. Cells were treated with 5 μM of 2-thio-6-azauridine 24 h post transfection. Viral p24 and 
virus infectivity measured as described in “Methods”. d The IC50 value of 2-thio-6-azauridine in HeLa and HeLa-shRNA-BST-2 cells. (*p < 0.05, t test)
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ubiquitin ligase K5, which can antagonize BST-2 in a sim-
ilar way as Vpu [20]. To examine whether 2-thio-6-azau-
ridine inhibits the degradation of BST2 by K5, plasmid 
expressing K5 was transfected to HeLa cells, followed 
by treating the cells with 5  μM of 2-thio-6-azauridine 
or 50  nM MG132 at 24  h post transfection. The sur-
face BST-2 level of cells was scored by flow cytometry 
at 48 h post transfection (Additional file  3B). As shown 
in Fig.  6b, the treatment of 2-thio-6-azauridine did not 










































Fig. 3 2-thio-6-azauridine reduces HIV-1 particle release. a Plasmids pNL-Luc-E- and pHIT/G were co-transfected with either pBST-2 or the control 
vector into 293T cells. Cells were treated with DMSO or different concentration of 2-thio-6-azauridine (0.05, 0.5, 5 μM) at 24 h post transfection. The 
cells and viruses in the culture supernatant were harvested separately at 48 h post transfection and then the HIV-1 Gag p55 in cell lysate and HIV-1 
Gag P24 in virions were detected by Western Blot. b By normalizing the Gag p55 level in virions, the P24 and VSV-G were detected by Western Blot
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results demonstrate that 2-thio-6-azauridine has no 
inhibitory effect upon K5 induced BST-2 degradation. 
Together, these data suggest that 2-thio-6-azauridine 
specifically blocks Vpu-induced degradation of BST-2.
2‑thio‑6‑azauridine does not affect the interaction  
of BST‑2 with Vpu
It is known that Vpu interacts with β-TrCP2, which is 
required for Vpu to down-regulate both CD4 and BST-
2. We first established a BRET2 assay to monitor Vpu 
and β-TrCP2 interaction. Vpu and β-TrCP2 were fused 
with EYFP and RLuc, respectively. The results of Fig. 7a 
showed strong interaction of these two proteins and that 
this interaction was not affected by 2-thio-6-azauridine. 
This observation was further confirmed by the results of 
co-immunoprecipitation. 293T cells were co-transfected 
with plasmids expressing Vpu and HA-tagged β-TrCP2. 
The cells were treated with DMSO or 2-thio-6-azauridine 
24 h post transfection. Cell lysates were immunoprecipi-
tated with HA antibody and detected by immunoblot-
ting with antibody against Vpu. The result showed that 
2-thio-6-azauridine did not affect the amount of Vpu 
bound to β-TrCP2 (Fig. 7b).
We next examined the effect of 2-thio-6-azauridine 
on the interaction between Vpu and BST2. In order to 
avoid the interference by Vpu-mediated BST-2 degrada-
tion, we also utilized a Vpu mutant Vpu (S52/56 N) that 
has two Serine residues mutated at positions 52 and 56. 
This mutated Vpu does not interact with β-TrCP2, but 
preserves the BST-2 binding activity [45]. The results of 
both BRET2 and co-IP experiments showed that 2-thio-
6-azauridine moderately increased the interaction of Vpu 
or Vpu (S52/56N) with BST-2 (Fig. 7c, d). Taken together, 




















Fig. 4 2-thio-6-azauridine reduces the infectivity of wild type HIV-1. 
CBMC were treated with AZ in different concentrations (0.008, 0.04, 
0.2, 1,5 μM) and infected with equal amount of NL4-3 viruses. Cell 
supernatants were harvested on day 3, day 5, day 7 and then ana-













































































Fig. 5 2-thio-6-azauridine dose not affect lysosomal-dependent 
degradation. a Models for the ubiquitin-mediated down-regulation 
of BST-2 by Vpu and for the ubiquitin-mediated down-regulation of 
IFNAR1 upon treatment of cells with IFN-α. Left panel Vpu interacts 
with BST-2 via the transmembrane domain and then induces BST-2 
ubiquitination through the recruitment of β-TrCP2-containing E3 
ubiquitin ligase complex, thus targeting the ubiquitinated proteins to 
lysosomal degradation. Right panel Treatment with IFN-α promotes 
phosphorylation of IFNAR1. Phosphorylated IFNAR1 recruits β-TrCP2-
containing E3 ubiquitin ligase complex and is ubiquitinated, then 
ubiquitinated proteins are degraded through lysosomal pathway. 
b Effect of 2-thio-6-azauridine on IFN-induced down-regulation of 
IFNAR1. HeLa cells were transfected with IFNAR1 expressing plasmid 
pcDNA3-IFNAR1-FLAG or empty vector as indicated. 40 h later, cells 
were treated as indicated for 4 h. Western blots of cell lysates were 
probed with anti-FLAG (top panel) and anti-β-actin (bottom panel) 
antibodies, respectively
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on the down-regulation process does not result from 
interfering with the interaction among Vpu, BST-2 and 
β-TrCP2.
2‑thio‑6‑azauridine reduces Vpu‑mediated ubiquitination 
of BST‑2
Since Vpu down-regulates BST-2 through recruit-
ing β-TrCP2 that causes BST-2 ubiquitination, we next 
investigated whether 2-thio-6-azauridine exerts any 
effect on Vpu-mediated BST-2 ubiquitination. To this 
aim, we co-expressed BST-2 and Vpu in the presence or 
absence of Myc-tagged ubiquitin in 293T cells. At 24  h 
post transfection, cells were treated with DMSO, 2-thio-
6-azauridine or ConA, and further cultured for another 
24 h. Lysates were then immunoprecipitated with BST-2 
antibody. Ubiquitin was detected by Western blotting. 
The results showed that 2-thio-6-azauridine obviously 
reduced the level of ubiquitinated BST-2, and the inhibi-
tory effect was further enhanced in the presence of ConA 
that block the degradation of BST-2 (Fig. 8). These results 
suggest that 2-thio-6-azauridine decreases Vpu-imposed 
ubiquitination of BST-2.
Discussion
In this study, we demonstrate for the first time that a 
small molecule compound 2-thio-6-azauridine inhib-
its Vpu-induced BST-2 degradation, increases BST-2 
level at the cell surface in the presence of Vpu and, as a 
result, inhibits wild type HIV-1 infection of BST-2-ex-
pressing cells. The anti-HIV-1 property of this compound 
depends on its capacity to diminish Vpu-induced BST-2 
ubiquitination.
2-thio-6-azauridine has been shown to inhibit RNA 
virus especially flaviviruses [including West Nile Virus 
(WNV), Yellow Fever Virus (YFV) and Japanese Enceph-
alitis Virus (JEV)], through blocking nucleoside triphos-
phate synthesis [40, 41]. 2-thio-6-azauridine inhibits 
orotidine monophosphate decarboxylase (ODCase). It 
also acts as a nucleoside analog and gets incorporated 
into the viral RNA, which leads to impaired transla-
tion of viral RNA [40, 46, 47]. These activities of 2-thio-
6-azauridine may account for the moderate inhibition of 
HIV-1 by this compound in the absence of BST-2 (Fig. 2). 
In addition, we also observed that viral production from 
Hela-shRNA-BST-2 was reduced by the compound to a 
greater extent than that from 293T cell. This might reflect 
different sensitivity of viral production to the inhibitory 
effect of 2-thio-6-azauridine in the two BST-2-deficient 
cell lines.
Given the potent antiviral activity of BST-2 and its 
constitutive expression in many human immunocytes, it 
is rational to devise a strategy that can expose wild type 
HIV-1 to this host restriction scheme. One strategy has 
been to identify small compounds that are able to block 
the BST-2 antagonist activity of HIV-1 Vpu. This strat-























































































Fig. 6 2-thio-6-azauridine dose not affect Vpu induced down-
regulation of cell surface CD4 and K5 induced BST-2 degradation. 
a pMX hCD4 plasmid expressing human CD4 was transfected to 
HeLa or HeLa-Vpu cells, followed by treating the cells with 5 μM of 
2-thio-6-azauridine at 24 h post transfection. The CD4-positive cells 
were scored by flow cytometry at 48 h post transfection. b KSHV 
K5 protein expressing plasmid pcDNA3.1-K5-HA was transfected to 
HeLa, followed by treating the cells with 5 μM of 2-thio-6-azauridine 
or 50 nM MG132 at 24 h post transfection. The cell surface BST-2 level 
was scored by flow cytometry at 48 h post transfection
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Fig. 7 Effect of 2-thio-6-azauridine on BST-2/Vpu/β-TrCP2 interaction. a Effect of 2-thio-6-azauridine on the interaction between Vpu and β-TrCP2. 
293T cells were co-transfected with pEYFP-N1-Vpu, pRluc-C3-β-TrCP2 and pBST-2, which express EYFP tagged Vpu, RLuc tagged β-TrCP2 and HA 
tagged BST-2 respectively. 24 h post transfection, cells were treated with DMSO or 5 µM 2-thio-6-azauridine for 24 h. BRET ratios were measured 
as described in “Methods”. BRET ratios are normalized relative to those in control cells that were treated with DMSO (left panel). b 293T cells were 
co-transfected with pVphu, pcDNA-HOS-HA and pcDNA-BST-2-FLAG which express Vpu, HA tagged β-TrCP2 and Flag tagged BST-2 respectively. 
24 h post transfection, cells were treated with DMSO and 5 µM 2-thio-6-azauridine for 24 h. Lysates were immunoprecipitated with 1 µg mouse 
anti-HA antibody followed by immunoblotting with rabbit anti-HA (top left panel) and Vpu antibody (bottom left panel). The pre-IP lysates represent 
1 % of the IP input and were also immunoblotted for β-actin as a loading control (bottom right panel). c Effect of 2-thio-6-azauridine on the interac-
tion between Vpu and BST-2. 293T cells were co-transfected with pRluc-C3-BST-2 and pEYFP-N1-Vpu, or pEYFP-N1-Vpu (S52/56N), which express 
Rluc tagged BST-2, EYFP tagged Vpu and EYFP tagged Vpu (S52/56N) respectively. 24 h post transfection, cells were treated with DMSO and 5 µM 
2-thio-6-azauridine for 24 h. BRET ratios were measured as described in “Methods”. Values presented here are the normalized BRET ratio relative to 
that treated with DMSO. The bar graphs represent the means of results of experiments performed at least three times, and the error bars represent 
standard deviations. d 293T cells were co-transfected with pVphu, pBST-2 (1:1). 24 h post transfection, cells were treated with DMSO and 5 µM 
2-thio-6-azauridine for 24 h. Lysates were immunoprecipitated with 1 µg mouse anti-HA antibody followed by immunoblotting with BST-2 (top left 
panel) and Vpu antibodies (bottom left panel). The pre-IP lysates represent 1 % of the IP input and were also immunoblotted for β-actin as a loading 
control (bottom right panel)
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the risk of causing cancer [48–50]. Our results show that 
2-thio-6-azauridine specifically inhibits Vpu-mediated 
BST-2 degradation without up-regulating the expression 
of BST-2, nor abrogating lysosomal degradation pathway. 
This compound thus represents a prototype that may 
be further developed as a new class of anti-HIV-1 drugs 
that function by targeting Vpu-mediated degradation of 
BST-2.
Our data show that 2-thio-6-azauridine increases 
BST-2 levels at the cell surface without modulating the 
interaction between Vpu and BST-2. Rather, the level of 
BST-2 ubiquitination is reduced by 2-thio-6-azauridine. 
These data suggest that binding to BST-2 is not sufficient 
for Vpu to antagonize BST-2, and that this antagoniza-
tion also involves Vpu-induced BST-2 ubiquitination and 
degradation. Despite the fact that the interaction among 
substrate, adaptor and E3 ligase is a prerequisite for ubiq-
uitination and efficient removal of target protein, factors 
other than the physical interaction may also regulate 
the process. Indeed, our group as well as another have 
reported that the N-terminal sequences of hA3G are able 
to bind to Vif while remaining resistant to Vif-induced 
depletion by Cul5/SCF complex, suggesting binding of Vif 
to hA3G is required, but not sufficient for hA3G degrada-
tion [51, 52]. A recent work reported that a host protein 
NORE1A forms a direct complex with β-TrCP, and sub-
strate-specifically stimulate the ubiquitin ligase activity 
of SCF (β-TrCP) toward its target protein β-catenin [53]. 
Similarly, an E3 ligase Mdm2 associate protein, p19ARF, 
was showed to specifically bind to Mdm2 and impairs 
the Mdm2-mediated degradation of p53. These observa-
tion therefore raise a possibility that 2-thio-6-azauridine 
might activate or inactivate a host regulator specific for 
Vpu-induced-ubiquitination of BST-2, without general 
interrupting the E3 ligase complex. Nevertheless, we also 
cannot exclude the possibility that pathways might exist 
other than β-TrCP2-dependent BST-2 degradation. For 
example, Janvier et al. reported that Vpu-induced BST-2 
degradation may involve the Endosomal Sorting Com-
plexes Required for Transport (ESCRT) machinery that is 
known to participate in sorting ubiquitinated membrane 
proteins toward lysosomal degradation [54].
Conclusion
We have discovered a lead compound, 2-thio-6-azau-
ridine, that specifically inhibits Vpu-induced BST-2 
down-regulation by decreasing Vpu-mediated BST-2 
ubiquitination. Given the great importance of interferon 
in protecting the host from virus infection, our study 
supports the concept of utilizing small molecule com-
pounds to neutralize viral antagonists and thereby expose 
viruses to the restriction of interferon-mediated innate 
immune responses.
Methods
Plasmid DNA, antibodies and reagents
Plasmid pVphu expresses codon-optimized Vpu [55]. 
Plasmids pEYFP-N1-Vpu, pRluc-C3-β-TrCP2, pEYFP-
N1-Vpu (S52/56N), pRluc-C3-BST-2 and pRluc-C3-β-
TrCP2 for BRET2 assay were kindly provided by Dr. Chen 
Liang (McGill AIDS Center, Montreal, Canada). Plasmids 
BST-2-HA
Vpu
C-Ub + + + + +
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Fig. 8 Effect of 2-thio-6-azauridine on Vpu-induced ubiquitination 
of BST-2. 293T cells were co-transfected with plasmid pBST-2, pVphu 
and CW7, which express BST-2, Vpu and C-myc tagged ubiquitin 
respectively (1:2:4). 24 h post transfection, cells were treated with 
DMSO, 5 µM 2-thio-6-azauridine and/or 50 nM Concanamycin A 
for another 24 h. Cell lysates were then immunoprecipitated with 
rabbit BST-2 antibody and treated with PNGase F, which was used 
to remove N-glycans from BST-2, followed by immunoblotting with 
mouse C-myc and HA antibody for ubiquitin and BST-2 detection 
respectively. The normalized ubiquitination Level of BST-2 was shown 
as bar graph
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pEYFP-N1-Vpu, pRluc-C3-β-TrCP2 and pRluc-C3-
BST-2 express EYFP tagged Vpu, Rluc tagged β-TrCP2 
and Rluc tagged BST-2 respectively. Plasmid pEYFP-
N1-Vpu (S52/56N) expresses EYFP tagged Vpu protein 
with amino acid substitutions of serines for asparagines 
at position 52 and 56, which keeps the ability of Vpu to 
bind BST-2 but cannot induce its degradation. The vesic-
ular stomatitis virus glycoprotein (VSV-G) expressing 
vector pHIT/G and HIV-1 proviral indicator construct 
pNL4-3Luc(R-E-) were kind gifts from Dr. Johnny He. 
Plasmid pNL-Luc-E− expresses firefly luciferase reporter 
gene in Env-deficient HIV-1 particles, which can be 
rescued in one-round infection experiment by VSV-G 
membrane protein provided in trans by plasmid pHIT/G 
[56]. Plasmid pBST-2, which expresses HA tagged BST-
2, was kindly provided by Dr. Paul D. Bieniasz. Plasmids 
pcDNA-HOS-HA and pcDNA3-IFNAR1-FLAG were 
generous gifts from Dr. Serge Y. Fuchs [43]. Plasmid 
CW7 which expresses C-myc ubiquitin was provided 
by Dr. Xiaofang Yu. Plasmid pcDNA3.1-K5-HA, which 
expresses HA tagged KSHV K5 protein, was a kind gift 
from Dr. Klaus Früh. pMX hCD4 expresses human CD4 
(Addgene, Catalog No. 14614). Plasmid shRNA-BST-2 
targeting bst-2 mRNA was purchased from Sigma. Vpu 
and BST-2 anti-serum were obtained from National 
Institutes of Health (NIH) AIDS Research & Reference 
Reagent Program. Luciferase antibody, β-actin antibody, 
HRP (horseradish peroxidase)-conjugated donkey anti-
rabbit and goat anti-rabbit IgG-FITC secondary antibod-
ies were purchased from Santa Cruz Co. Concanamycin 
A, MG132 and doxycycline were purchased from Sigma 
(St. Louis, MO). Cord blood mononuclear cells (CBMC) 
were isolated from healthy infants after uncomplicated 
births. The HIV-1 proviral DNA clone HIV-1NL4–3  was 
obtained from the NIH AIDS Research and Reference 
Reagent Program.
Cell culture and transfection
HeLa and 293T cells were cultured in Dulbecco’s Modi-
fied Eagle’s Medium with the addition of 10  % fetal 
bovine serum (FBS) (Invitrogen). HeLa-Vpu cell line was 
established and cultured as previously described [39]. 
SupT1 cells were maintained in RPMI-1640 containing 
10  % FBS. 293T and HeLa cells were transfected using 
LipofectAMINE 2000 (Invitrogen) or Fugene HD trans-
fection reagents (Roche) according to the manufacturer’s 
instructions.
BST‑2 knockdown HeLa cell line
HeLa cells were transfected with shRNA-BST-2 plasmid, 
then selected with 400  μg/ml G418 24  h post transfec-
tion. Limited dilution was conducted to obtain single cell 
colonies. One clonal cell line shRNA-BST-2 has almost 
no BST-2 expression and was therefore used in the subse-
quent experiments.
Single‑round HIV‑1 replication assay
HeLa or HeLa-Vpu cells (2  ×  105) were co-transfected 
with 0.6  μg of pNL-Luc-E− or pNL-Luc-E−-Vpu− and 
0.4 μg of pHIT/G. After 48 h, the viral supernatant was 
harvested by filtration through a 0.45  μm filter and the 
amount of viruses was determined by measuring the 
level of p24 antigen using ELISA (Biomerieux). HIV-1 
of the same p24 amounts was used to infect SupT1 cells 
(1 ×  105) in 96-well plates. The SupT1 cells were lysed 
at 48 h post infection and the firefly luciferase activities 
were measured to determine the level of HIV-1 infection.
Measuring viral reverse transcriptase activity
HIV-1 stocks were produced and quantified as previ-
ously described [42]. HIV-1 infection of primary cells 
followed the procedure as referenced [57]. Viral reverse 
transcriptase activity was measured to determine the 
amounts of virus in culture supernatants. Briefly, 10 μl 
of culture supernatant was mixed with 40  μl of reac-
tion buffer containing 0.5  unit/ml poly(rA)-oligo(dT) 
(Midland Certified Reagent Co.) and 0.1  mCi/ml [3H]
dTTP (Perkin-Elmer). After a 3-h incubation at 37  °C, 
reactions were terminated by the addition of 10  % 
trichloroacetic acid (TCA). The precipitated oligonucle-
otides were collected by filtering the reaction mixtures 
through Millipore MultiScreen Glass Fiber FC plates 
(Millipore). After two washes with 10  % TCA and one 
wash with ethanol, levels of 3H that were retained on 
the filters were scored in a liquid scintillation counter 
(Perkin-Elmer).
Cell‑based ELISA
HeLa or HeLa-Vpu cells were plated into 96-well plates 
at 1 ×  104 cells/well. After 48  h, the cells were washed 
twice with phosphate buffered saline and fixed in 4  % 
paraformaldehyde for 20 min at room temperature. Then 
cells were washed with phosphate buffered saline and 
incubated with 50  μl BST-2 antiserum (1:5000) for 1  h 
at 37  °C. Cells were washed four times with phosphate 
buffered saline. Next, cells were incubated with 50  μl 
HRP-conjugated donkey anti-rabbit secondary anti-
body (1:6000) for 0.5  h at 37  °C, and then washed four 
times with phosphate buffered saline. The cell-bound 
secondary antibodies were detected using 100  μl/well 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate solu-
tion for 30 min at room temperature. The reactions were 
stopped by adding 50 μl/well 0.5 M H2SO4, followed by 
immediately measuring absorption at 450 nm.
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Western blotting
Cellular samples were suspended in loading buffer con-
taining SDS and dithiothreitol and boiled for 10  min. 
Total proteins were separated on 12  % polyacrylamide 
SDS gels. Proteins were transferred onto nitrocellulose 
membranes and blotted with the antibodies against Vpu 
(1:1000), BST-2 (1:5000) or β-actin (1:1000). The mem-
branes were further incubated with either a HRP-con-
jugated goat anti-mouse antibody or a HRP-conjugated 
donkey anti-rabbit antibody, followed by detection with 
enhanced chemiluminescence.
Co‑immunoprecipitation assay
293T cells were collected and lysed in 350 μl TNT buffer 
(20  mM Tris–HCl pH 7.5, 200  mM NaCl, 1  % Triton 
X-100) 48 h post transfection. The supernatants of equal 
amounts of protein were incubated with 3  μl of anti-
HA antibody for 16  h at 4  °C, followed by the addition 
of protein A-Sepharose (Amersham Biosciences) for 2 h. 
The immunoprecipitated materials were then washed 
three times with TNT buffer and twice with phosphate 
buffered saline. After the final supernatant was removed, 
30 μl of 2 × sample buffer (120 mm Tris–HCl (pH 6.8), 
20  % glycerol, 4  % SDS, 2  % β-mercaptoethanol, and 
0.02  % bromophenol blue) was added, and the pre-
cipitates were then boiled for 15 min to release the pre-
cipitated proteins. After centrifugation, the resulting 
supernatants were analyzed in Western blots.
BRET2 assay
The BRET2 assay was used to measure protein–protein 
interaction. 293T cells were co-transfected with pEYFP-
N1-Vpu and pRluc-C3-β-TrCP2 or with pEYFP-N1-Vpu 
and pBST-2. Cells were harvested 40  h after transfec-
tion, then distributed into 96-well microplates (white 
Optiplate; Perkin-Elmer) with a density of 2 × 105 cells/
well. Substrate DeepBlueC (Perkin-Elmer) was injected 
at a final concentration of 5 μM. The signals at 480 and 
535  nm were measured sequentially on a Model 680 
Microplate Reader (Berthold Technologies). BRET ratio 
was calculated using the equation below, [(emission at 
535 nm/emission at 480 nm) in cells expressing the hRluc 
and hEYFP fusion proteins]—[(emission at 535 nm/emis-
sion at 475 nm) in cells expressing hRluc alone].
Flow cytometry
Flow cytometry was performed as described previously 
[31]. Briefly, Cells were trypsinized and resuspended in a 
flow cytometry buffer (3  % fetal bovine serum in phos-
phate buffered saline), then stained with CD4 antiserum 
(1:800) and goat anti-rabbit IgG-FITC secondary anti-
body (1:200) on ice for 1 h, followed by fixation with 1 % 
paraformaldehyde and analysis on a FACS calibur system.
Real‑time RT‑PCR
Total RNA was extracted from cells using TRIZOL Rea-
gent (Invitrogen). RNA was converted to cDNA using 
M-MLV Reverse Transcriptase (Promega) with random 
primers. The cDNAs were quantified using SsoFast Eva-
Green Supermix (Bio-Rad) and Bio-Rad iCycler iQ5 Real-
Time PCR systems. Primer sequences for cDNAs were 
as follows, BST-2 sense: CTGCAACCACACTGTGATG, 
antisense: ACGCGTCCTGAAGCTTATG [37], GAPDH 
sense: GTCCACTGGCGTCTTCACCA, antisense: GTG-
GCAGTG ATGGCATGGAC [35]. GAPDH mRNA was 
quantified in order to normalize the level of bst-2 mRNA.
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